Researchers identify specific immune markers, like activated monocytes and cytokines, that drive cognitive decline after viral infections across various diseases.

A large international clinical trial has unveiled a promising new option for people living with highly treatment-resistant HIV.

Drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies for enhanced suppression of human immunodeficiency virus (HIV) infection. By targeting ...

HIV can remain in the fluid surrounding the brain even after a decade on antiretroviral treatment, which may help explain persistent cognitive problems in some people with undetectable viral load, ...

A panelist discusses how CD4 counts serve as measures of immune system status that typically increase by about 200 in the first year of antiretroviral therapy. Although there can be laboratory ...

Three children still aviremic off ART provide hope that more cases are possible ...